ストックスクリーナーアプリを入手
1.55
3.13%
-0.05
アフターアワーズ：
1.62
0.07
+4.52%
前日終値:
$1.60
開ける：
$1.6
24時間の取引高:
122.05K
Relative Volume:
0.32
時価総額：
$57.98M
収益：
-
当期純損益:
$-40.56M
株価収益率:
-1.3248
EPS:
-1.17
ネットキャッシュフロー:
$-35.28M
1週間 パフォーマンス:
-6.63%
1か月 パフォーマンス:
-9.36%
6か月 パフォーマンス:
-50.00%
1年 パフォーマンス:
-71.14%
1日の値動き範囲:
$1.50
$1.6499
1週間の範囲:
$1.50
$1.73
52週間の値動き範囲:
$1.302
$6.68
Pds Biotechnology Corporation Stock (PDSB) Company Profile
名前
Pds Biotechnology Corporation
セクター
電話
800-208-3343
住所
303A COLLEGE ROAD EAST, PRINCETON
PDSB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
1.55 | 57.98M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-01 | 開始されました | B. Riley Securities | Buy |
| 2021-06-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-11-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 開始されました | Alliance Global Partners | Buy |
| 2020-03-09 | 開始されました | Noble Capital Markets | Outperform |
| 2019-10-24 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Pds Biotechnology Corporation (PDSB) 最新ニュース
Clinical Trials News Live Feed - StockTitan
PDS Biotech set for Phase 3 trial in HPV-positive cancer treatment - MSN
FDA approves PDS Biotech's Phase 3 trial design for cancer therapy - MSN
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Marketscreener.com
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - The Manila Times
PDS Biotech Advances Novel HPV Cancer Treatment to Phase 3 Trial with FDA Fast Track Status | PDSB Stock News - StockTitan
Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance
PDS Biotechnology Corporation (NASDAQ: PDSB): Hidden Gems In A Time Of Volatility - Stocks Register
Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Inspirion Wealth Advisors LLC Sells 270,862 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - MarketBeat
PDSB stock touches 52-week low at $1.51 amid market challenges - Investing.com Nigeria
Spero Therapeutics names Esther Rajavelu as Interim President and CEO (NASDAQ:SPRO) - Seeking Alpha
Geode Capital Management LLC Acquires 37,142 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Ball Co. (NYSE:BALL) Shares Sold by GAMMA Investing LLC - Defense World
PDS Planning Inc Has $23.21 Million Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Meet Gauzy and Research Frontiers at CES This Week to See the Latest in SPD-SmartGlass Products and Technology - Quantisnow
State Street Corp Sells 18,700 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp Announces Pricing Of Public Offering Of About $12 mln Shares - Reuters
PDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC Wainwright - MarketBeat
DBV stock rallies post-market on FDA Viaskin update (NASDAQ:DBVT) - Seeking Alpha
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
PDS Biotech Grants Stock Options to New Clinical Employee Under Inducement Plan - StockTitan
PDSBPDS Biotechnology Corporation Latest Stock News & Market Updates - StockTitan
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET - The Manila Times
PDS Biotech Announces Expert Panel on HPV16 Cancer Treatment Phase 3 Trial - StockTitan
A share offer that's hard to refuse - Investors Chronicle
BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors - Newsfile
PreveCeutical Medical Appoints Biopharma Veteran Stephen Glover to BioGene Board - StockTitan
Research Analysts Issue Forecasts for PDSB FY2024 Earnings - Defense World
FY2024 EPS Estimate for PDS Biotechnology Lowered by Analyst - MarketBeat
Kronos Bio stock in focus on CEO change, layoffs (KRON:NASDAQ) - Seeking Alpha
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround - Yahoo Finance
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2024 Earnings Call Transcript - MSN
PDS Biotechnology’s (PDSB) Buy Rating Reiterated at HC Wainwright - Defense World
Versamune HPV Could Bolster Long-Term Efficacy With Pembrolizumab in HPV16-Driven HNSCC - OncLive
PDS Biotechnology's (PDSB) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference - StockTitan
PDS Biotechnology Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
PDS Biotechnology Corporation (PDSB) Quarterly 10-Q Report - Quartzy
PDS Biotechnology: Q3 Earnings Snapshot - New Haven Register
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... By GuruFocus - Investing.com Canada
PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks
Earnings call: PDS Biotech reports progress in HPV cancer trials By Investing.com - Investing.com Canada
Earnings call: PDS Biotech reports progress in HPV cancer trials - Investing.com
PDSB stock touches 52-week low at $2.21 amid market challenges - Investing.com India
PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications - MarketWatch
PDS Biotechnology Corporation Provides Clinical Programs Update - Marketscreener.com
Pds Biotechnology Corporation (PDSB) 財務データ
収益
当期純利益
現金流量
EPS
0.82%
0.53%
大文字化:
|
ボリューム (24 時間):